Novavax Inc
(WBO:NVAX)
€
9.276
-0.09 (-0.96%)
Market Cap: 1.49 Bil
Enterprise Value: 734.28 Mil
PE Ratio: 0
PB Ratio: 0
GF Score: 47/100 Novavax Inc at TD Cowen Health Care Conference Transcript
Mar 08, 2023 / 02:50PM GMT
Georgi Nenov Yordanov
TD Cowen, Research Division - Specialty Pharma Associate
Joining us at TD Cowen Healthcare Conference. My name is Georgi Yordanov, one of the biopharma analysts. And I'd like to welcome John Trizzino, Chief Commercial Officer at Novavax.
Questions & Answers
Georgi Nenov Yordanov
TD Cowen, Research Division - Specialty Pharma Associate
So maybe, John, kind of like taking a step back, 2022 obviously shaped up to be quite of a turbulent year, a lot of evolving pieces, some high expectations from your team in terms of participating in the pandemic market. But 2023 is shaping to be quite different. We're entering the endemic market. So maybe can you just talk about the key priorities for Novavax as we enter 2023 and beyond?
John Joseph Trizzino
Novavax, Inc. - Executive VP and Chief Business & Commercial Officer
Yes. So first of all, thanks, Georgi, for having timing me here. I'm happy to talk about our successes and what the future looks like. And so while '22 was challenging in
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot